IGF-1 LR3 is a modified analogue of insulin-like growth factor-1, engineered with a Glu3→Arg substitution and a 13-residue N-terminal extension that markedly reduces binding to IGF-binding proteins an...
IGF-1 LR3 is a modified analogue of insulin-like growth factor-1, engineered with a Glu3→Arg substitution and a 13-residue N-terminal extension that markedly reduces binding to IGF-binding proteins and extends bioavailability relative to native IGF-1. It binds and activates the IGF-1 receptor, triggering downstream PI3K/Akt and MAPK/ERK signaling studied in relation to cellular proliferation, protein synthesis, and anabolic tissue signaling.
Journal of Developmental Origins of Health and Disease · 2023
Acute IGF-1 LR3 infusion into late-gestation fetal sheep suppressed glucose-stimulated insulin secretion in vivo, but isolated islets from treated animals retained normal secretory capacity, indicating a transient extrinsic effect rather than lasting beta-cell damage.
View Source →International Journal of Molecular Sciences · 2022
Using IGF-1 LR3 as the receptor-activating ligand, glycosylation-deficient cells showed reduced surface IGF-1R and blunted ERK1/2 phosphorylation, identifying N-linked glycosylation as required for normal IGF-1R/ERK signaling.
View Source →-01M0WTTEK6VAQXQTKZYJM09J2N.png)